Kylie Kavanagh to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Kylie Kavanagh has written about Dose-Response Relationship, Drug.
Connection Strength
0.281
-
Kavanagh K, Flynn DM, Nelson C, Zhang L, Wagner JD. Characterization and validation of a streptozotocin-induced diabetes model in the vervet monkey. J Pharmacol Toxicol Methods. 2011 May-Jun; 63(3):296-303.
Score: 0.083
-
Kavanagh K, Flynn DM, Jenkins KA, Zhang L, Wagner JD. Restoring HSP70 deficiencies improves glucose tolerance in diabetic monkeys. Am J Physiol Endocrinol Metab. 2011 May; 300(5):E894-901.
Score: 0.082
-
Kavanagh K, Brown KK, Berquist ML, Zhang L, Wagner JD. Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes. Metabolism. 2010 Jun; 59(6):914-20.
Score: 0.077
-
Wagner JD, Zhang L, Kavanagh K, Ward GM, Chin JE, Hadcock JR, Auerbach BJ, Harwood HJ. A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys. J Pharmacol Exp Ther. 2010 Oct; 335(1):103-13.
Score: 0.020
-
Wagner JD, Shadoan MK, Zhang L, Ward GM, Royer LJ, Kavanagh K, Francone OL, Auerbach BJ, Harwood HJ. A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys. J Pharmacol Exp Ther. 2010 Jun; 333(3):844-53.
Score: 0.019